FDA advisory panels to drop vote on approvability in favour of risk-benefit assessment
This article was originally published in Clinica
The US Food and Drug Administration is to change to the way its medical device advisory committees discuss data and information during public hearings on products under review for premarket approval (PMA). The change will apply from 1 May.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.